Extended Data Figure 2. Demographics, CD4⁺ T cells during study period in participants and pharamacokinetics of 3BNC117 and 10–1074.

a, Table showing baseline participant demographics. *NNRTI - Non-nucleoside reverse transcriptase inhibitor. b, Absolute CD4⁺ T cell counts and percentage of CD4⁺ T cells among CD3⁺ T cells at screening (n=15), day 0 (n=15), at the time of viral rebound (n=13) and at the end of the study are shown (n=15) (see also Supplementary Table 2). The last available time point after resuppression was used as end of the study time point for the participants that reinitiated ART. Red lines indicate mean and error bars indicate standard deviation. P values were obtained using a two-tailed paired t-test comparing CD4⁺ T cell counts between day 0 and the time of viral rebound. c,d, 3BNC117 (red) and 10–1074 (blue) levels in serum (n=15) as determined by TZM-bl assay (c) and ELISA (d). Curves indicate mean serum antibody concentrations and error bars represent standard deviation. Red and blue triangles indicate 3BNC117 and 10–1074 infusions, respectively. In the TZM-bl assay, lower limits of detection were 0.46 µg/ml and 0.01 µg/ml for 3BNC117 and 10–1074, respectively (c). In the ELISA, lower limits of detection were 0.78 µg/ml and 0.41 µg/ml, respectively (d). In cases where participants only received 2 infusions due to early viral rebound (9245, 9249 and 9253), only antibody concentrations up to the second infusion were included. Half-life of each bNAb is indicated in days. e,f, Half-lives of both antibodies as measured by TZM-bl assay (e) and ELISA (f). Each dot represents a single participant. The half-lives of both antibodies from the 15 participants enrolled in the study are represented. Black lines indicate the mean value and standard deviation (n=15). P values were obtained using a two-tailed unpaired t-test comparing the two antibodies.